These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36279907)

  • 1. Impact of cholesterol and Lumacaftor on the folding of CFTR helical hairpins.
    Schenkel M; Ravamehr-Lake D; Czerniak T; Saenz JP; Krainer G; Schlierf M; Deber CM
    Biochim Biophys Acta Biomembr; 2023 Jan; 1865(1):184078. PubMed ID: 36279907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor.
    Krainer G; Schenkel M; Hartmann A; Ravamehr-Lake D; Deber CM; Schlierf M
    J Biol Chem; 2020 Feb; 295(7):1985-1991. PubMed ID: 31882543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positional dependence of non-native polar mutations on folding of CFTR helical hairpins.
    Wehbi H; Gasmi-Seabrook G; Choi MY; Deber CM
    Biochim Biophys Acta; 2008 Jan; 1778(1):79-87. PubMed ID: 17949679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural effects of extracellular loop mutations in CFTR helical hairpins.
    Chang YH; Stone TA; Chin S; Glibowicka M; Bear CE; Deber CM
    Biochim Biophys Acta Biomembr; 2018 May; 1860(5):1092-1098. PubMed ID: 29307731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the extracellular loop in the folding of a CFTR transmembrane helical hairpin.
    Wehbi H; Rath A; Glibowicka M; Deber CM
    Biochemistry; 2007 Jun; 46(24):7099-106. PubMed ID: 17516627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants.
    McDonald EF; Sabusap CMP; Kim M; Plate L
    Mol Biol Cell; 2022 Jun; 33(7):ar62. PubMed ID: 35389766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs.
    Abu-Arish A; Pandžić E; Luo Y; Sato Y; Turner MJ; Wiseman PW; Hanrahan JW
    J Cell Sci; 2022 Mar; 135(5):. PubMed ID: 35060604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.